Skip to content

Johanna Keeler

3 papers in the library · 108 citations · publishing 2021-2022

Papers

"This Is Something That Changed My Life": A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders.

Frontiers in psychiatry January 1, 2021 O Merve Mollaahmetoglu, Johanna Keeler, Katherine J Ashbullby et al. 62 citations

Ketamine treatment, provided in a supportive clinical setting, led to a significant change in participants' relationship with alcohol. Interviews with 12 people who received up to three ketamine infusions (0.8 mg/kg) as part of a Phase II randomized controlled trial revealed six key themes: multifaceted motivations for joining the trial; the influence of set and setting on the acute experience; inherent contradictions such as dissociation versus feelings of connection; rapidly fluctuating experiences; meaningful, mystical, and spiritual experiences; and transformational effects of the infusions. Participants reported that ego dissolution and dissociation were linked to these transformative changes. The authors suggest that the acute psychoactive effects of ketamine transcend its traditional label as a dissociative anesthetic and recommend developing new measures to capture the full spectrum of these effects.

Perspectives on psychedelic treatment and research in eating disorders: a web-based questionnaire study of people with eating disorders

Journal of Integrative Neuroscience September 30, 2021 Fiona Harding, Mathieu Seynaeve, Johanna Keeler et al. 18 citations

About 1.25 million people in the UK have an eating disorder, but current treatments have limited effectiveness, prompting interest in new approaches. A web survey of 200 people with eating disorders found that 70% had used complementary therapies to manage their condition. Participants viewed psychedelic research as worthwhile but expressed moderate concern. To address these concerns, they suggested education about psychedelics and their psychiatric use, endorsement from professionals, and a safe, monitored environment with strong patient-therapist rapport. These findings inform future trials of psychedelics for eating disorders.